Clareo Health | Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate
Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
This study is currently available in Canada only.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Post-menopausal women 18 years of age or above with proven diagnosis of advanced adenocarcinoma of the breast (locoregionally recurrent or metastatic disease)
ER-positive and/or PR-positive tumor based on local laboratory results
HER2-negative tumor based on local laboratory results
Patients must be appropriate candidates for letrozole therapy (Canada: first-line patients only)
You may not be if
Patients who have previously participated in a palbociclib trial or who have received prior treatment with any CDK inhibitor
